The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
Edward Samuel James
No relevant relationships to disclose
Gina Chung
No relevant relationships to disclose
Noelle Marie Sowers
No relevant relationships to disclose
Mary Beth Clark
No relevant relationships to disclose
Rebecca Lilian
No relevant relationships to disclose
Gineesha Abraham
No relevant relationships to disclose
Susan Chmael
No relevant relationships to disclose
Michelle Cappiello
No relevant relationships to disclose
Michael DiGiovanna
No relevant relationships to disclose
Erin Wysong Hofstatter
No relevant relationships to disclose
Tara Beth Sanft
No relevant relationships to disclose
Gary M. Israel
No relevant relationships to disclose
Lajos Pusztai
No relevant relationships to disclose
Lyndsay Harris
No relevant relationships to disclose
Maysa M. Abu-Khalaf
No relevant relationships to disclose